Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

Great response. I have a background in finance & strategy and think that McKinsey's research is very high level and cannot entirely be applied here for several reasons. To keep this short let me ask you this question. Elite's true end customer is a patient (could be argued it is a physician, but irrelevant) requiring pain medication. Today that patient is receiving non-ADF pain prescriptions and their needs are already being met. It is illogical to expect a spike in pain needs out of the blue as soon as Elite gets approval (I assume they will). If the end consumer doesn't change, the market doesn't change, where then will Elite be creating revenues if it is not 100% through cannibalization of current non-ADFs that are servicing today's pain needs? Interested in your thoughts. Good dialogue.